Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2009

View Archived Issues

Teva submits BLA to FDA for XM-02 for chemotherapy-induced neutropenia

Kalbitor approved in U.S. for hereditary angioedema

Plethora Solutions and Columbia Laboratories execute marketing agreement for Striant SR

Acacia's subsidiary enters into license agreement with Boston Scientific

Ardea Biosciences reports results from combination trial of RDEA-594 and febuxostat

Pfizer and Astellas launch Caduet combination tablets in Japan

Sitaxentan reduces post-CPB acute kidney injury in porcine model

Phase III data reported for ticagrelor vs. clopidogrel in platelet aggregation

MK-1775 exhibits synergism with gemcitabine in pancreatic tumors in vivo

TRIN-2755 exhibits antitumor activity in multiple xenograft mouse models

Interim data presented from AV-412 phase I trial in advanced solid tumors

Data from phase I study on AS-703569 disclosed at 2009 AACR-NCI-EORTC meeting

Takeda reports results from first half of 2009 ended September 30

Merck KGaA describes TGF-beta receptor inhibitors as oncolytics

Advinus Therapeutics discloses novel adenosine receptor antagonists

Biovitrum discovers novel GPR119 agonists for the treatment of obesity

Novel antibacterial agents presented by Actelion

Keryx Biopharmaceuticals' perifosine receives FDA fast track designation

FDA lifts clinical hold of CytRx's arimoclomol in amyotrophic lateral sclerosis

DermaGen's antimicrobial peptide successful in phase I/IIa clinical trials in atopic dermatitis

GlaxoSmithKline files for approval of Rotarix vaccine in Japan

EMEA accepts clinical development plan for DiaPep-277

Vasopharm recruits first patient in a phase IIa trial of VAS-203

TiGenix completes acquisition of Orthomimetics

Wilex receives preliminary results of phase III Redectane trial

Hemispherx Biopharma receives FDA complete response letter for Ampligen NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...